Friday, Jun 7, 1996

Genentech Discontinues Pursuit of Actimmune for Renal Cell Carcinoma

Phase III data analysis shows lack of demonstrable benefit

South San Francisco, Calif. -- June 7, 1996 --

Genentech, Inc. (NYSE: GNE) today announced that it has discontinued pursuing Actimmune® (Interferon gamma-1b) for renal cell carcinoma because analysis of Phase III clinical data showed no significant benefit of the product for this targeted indication.

Data were analyzed from two Phase III trials: an open-label, non-randomized U.S. study and a randomized, double-blinded, placebo-controlled Canadian study. The overall response rate was similar in both studies. The placebo-controlled Canadian trial demonstrated no statistically significant difference in response rate, response duration, time to progression, or survival between the placebo group and patients receiving Actimmune.

Actimmune is currently marketed in the United States for the treatment of chronic granulomatous disease (CGD). These findings do not change the current treatment recommendations for patients with CGD.

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures, and markets human pharmaceuticals for significant unmet medical needs. The company is headquartered in South San Francisco, California, and is traded on the New York and Pacific Stock Exchanges under the symbol GNE.

# # #